{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:49Z","timestamp":1788401629495,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128304","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:16:58Z","timestamp":1770693418000},"page":"128304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial"],"prefix":"10.1016","volume":"76","author":[{"given":"Temitope","family":"Oyedele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apinya","family":"Vutikullird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Jepson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey Cromer","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Jah","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2026.128304_bb0005","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1086\/511989","article-title":"The 1918 influenza pandemic: insights for the 21st century","volume":"195","author":"Morens","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128304_bb0010","unstructured":"World Health Organization. COVID-19 vaccine tracker and landscape; https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines; 2023."},{"issue":"6","key":"10.1016\/j.vaccine.2026.128304_bb0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"658","key":"10.1016\/j.vaccine.2026.128304_bb0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4130","article-title":"Durable protection against the SARS-CoV-2 omicron variant is induced by an adjuvanted subunit vaccine","volume":"14","author":"Arunachalam","year":"2022","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128304_bb0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2026.128304_bb0030","unstructured":"Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1\u201362."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128304_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41533-025-00414-0","article-title":"Differences in clinical characteristics between coronavirus disease 2019 (COVID-19) and influenza: a systematic review and meta-analysis","volume":"35","author":"Han","year":"2025","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.vaccine.2026.128304_bb0040","unstructured":"U.S. Centers for Disease Control and Prevention. COVID-19 can surge throughout the year; https:\/\/www.cdc.gov\/ncird\/whats-new\/covid-19-can-surge-throughout-the-year.html; 2024."},{"key":"10.1016\/j.vaccine.2026.128304_bb0045","article-title":"Covid-19: Pfizer-BioNTech vaccine is rolled out in US","volume":"371","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128304_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128304_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128304_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2373","article-title":"Recent insights into SARS-CoV-2 omicron variant","volume":"33","author":"Silva","year":"2023","journal-title":"Rev Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128304_bb0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: Passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128304_bb0070","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128304_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41541-023-00707-w","article-title":"Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery","volume":"8","author":"Liu","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128304_bb0080","article-title":"In vivo assembly of nanoparticles achieved through synergy of structure-based protein engineering and synthetic DNA generates enhanced adaptive immunity","volume":"7","author":"Xu","year":"2020","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128304_bb0085","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"7456","key":"10.1016\/j.vaccine.2026.128304_bb0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128304_bb0095","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128304_bb0100","article-title":"Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system","volume":"6","author":"Mohsen","year":"2018","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128304_bb0105","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","article-title":"Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses","volume":"56","author":"Ols","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128304_bb0110","unstructured":"Merck and Co. I. GARDASIL\u00ae 9 Prescribing Information; https:\/\/www.fda.gov\/media\/90064\/download; 2014."},{"key":"10.1016\/j.vaccine.2026.128304_bb0115","unstructured":"Bavarian Nordic A\/S. VIMKUNYA\u2122 Prescribing Information; https:\/\/www.fda.gov\/media\/185477\/download; 2025."},{"key":"10.1016\/j.vaccine.2026.128304_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1123805","article-title":"Platforms, advances, and technical challenges in virus-like particles-based vaccines","volume":"14","author":"Gupta","year":"2023","journal-title":"Front Immunol"},{"issue":"6965","key":"10.1016\/j.vaccine.2026.128304_bb0125","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128304_bb0130","article-title":"SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity","author":"Joyce","year":"2021","journal-title":"bioRxiv"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128304_bb0135","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"Richman","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128304_bb0140","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2026.128304_bb0145","unstructured":"BioNTech Manufacturing GmbH., Pfizer Inc. Comirnaty\u00ae Prescribing Information; https:\/\/www.fda.gov\/vaccines-blood-biologics\/comirnaty; 2025."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128304_bb0150","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2190690","article-title":"Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults","volume":"19","author":"Yassini","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128304_bb0155","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2026.128304_bb0160","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128304_bb0165","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128304_bb0170","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1016\/j.vaccine.2023.10.065","article-title":"Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults","volume":"41","author":"Chen","year":"2023","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:41:55Z","timestamp":1777398115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"alternative-id":["S0264410X2600112X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128304","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AstraZeneca. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128304"}}